Atrian Bakers’s bread Tritordeum, made with the new cereal Agrasys, nominated to the Carrefour Innovation Awards Blog Post

A new type of bread  produced by Atrian Bakers  and made with Tritordeum,  has been nominated for the 2015 Carrefour Innovation Awards. The new type of bread will be subjected to population vote until the 21st of June. Tritordeum cereal is the first man-made cereal without genetic modification suitable for human consumption. Developed in the late 70s by a group of scientists from the Institute for Sustainable Agriculture (IAS) of the Higher Council for Scientific Research (CSIC)), and after 30 years of research, Agrasys -a spin-off company based at the Barcelona Science Park, founded by researchers from the IAS and the industry, launched the new bread to the market in April 2013.

Ordesa saw turnover grow to €112.4 millions, up 4.7%, in 2014 Blog Post

Laboratorios Ordesa today announced its results for the 2014 year, which reveal a growing trend mainly due to increased sales, cutting structural costs, implementing more efficient sales policies and consolidating foreign markets the company had opened in previous years. Since 2007, the Ordesa Group has a R&D&i center at Barcelona Science Park, from where the company actively participates in clinical studies and national and international research projects in the areas of immunology and cognitive development. The elaboration of hydrolyzed cereals, liquid milk, or the launching of the first porridge with bifidus effect, and supplemented infant formulas are some of the results from these projects. 

Ordesa leads the Smartfoods project Blog Post

The Centre for the Development of Industrial Technology (CDTI) has granted the Smartfoods industrial research project for the development of smart food to a consortium of companies led by Ordesa from this R&D&i center at Parc Científic de Barcelona.The aim of this research is the design of foods and screening tests that will help reduce the risk of some of the most frequently occurring diseases that will cause 3 of every 4 deaths in 2020.

Iproteos closes the first ‘crowdfunding’ campaign of the Spanish biotech sector Blog Post

The biotech Iproteos -located at the Parc Cientific de Barcelona- has managed to successfully close an innovative funding campaign based on equity crowdfunding with the aim of raising € 100,000 for the development of a new drug to stop progression and reverse the cognitive deficits associated with schizophrenia: IPR019. The funds raised will allow the biotech -a spin-off from the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona) – complete the preclinical non-regulatory stage of the compound to begin clinical trials in 2016.


SOM Biotech develops a drug for Amyloidosis in collaboration with the Vall d’Hebron Research Institute Blog Post

The and the biopharmaceutical , based at the Parc Científic de Barcelona (PCB), have signed an agreement to jointly develop the clinical phase of a drug for transthyretin Amyloidosis (ATTR). The collaboration starts with the execution of a proof of concept in 20 healthy voluntiers and patients affected by the polineuropatic form of the disease – which will confirm the efficacy and safety of compound SOM0226. The product, a repositioned drug developed by SOM Biotech, may be effective for all variants of the ATTR and has been designated recently orphan drug by the Food and Drug Administration (FDA) of United States.


Agrasys launches to the market the first newly created cereal in the world for human consumption Blog Post

Agrasys, a spin-off of the Spanish National Research Council (CSIC) located at the Barcelona Science Park, has launched to the market Tritordeum, the first newly created cereal marketed in the world for human consumption. The official presentation took place at Hotel Claris in Barcelona, with a welcome by members of Agrasys and the participation of master baker Josep A. Ribas, author of the Cruixent artisan breads bakery, and Chef Josep M. Freixa, presently head of the Tradició Freixa Restaurant (awarded with a Michelin star).

Full de Ruta cap a la curació de l’Esclerosi MúltipleTO TRANSLATE >>> Blog Post

Fundació GAEM, Grup d’Afectats d’Esclerosi Múltiple –que lé la seva seu al Parc Científic Barcelona– presenta la plataforma Full de Ruta cap a la curació de l’Esclerosi Múltiple”. L’objectiu d’aquesta iniciativa és promoure un programa nou per finançar projectes de recerca que cobreixin totes les etapes cap a la curació.

L’ Espai Movistar s’ al costat del PCBTO TRANSLATE >>> Blog Post

L’Espai Movistar, fins fa poc ubicat al Fòrum, s’instal·larà a partir del novembre al costat del nou Edifici Satèl·lit del Parc Científic de Barcelona, (PCB), concretament a la Plaça Bederrida, entre els carrers Pau Gargallo, Martí i Franquès, Baldiri i Reixach i Pascual Vila. El seu trasllat es va acordar en un conveni que la UB va signar a finals de juliol amb l’Ajuntament de Barcelona.